Recurrent Salmonella typhimurium bacteremia associated with the acquired immunodeficiency syndrome.
Seven Haitian and one white patient with the acquired immunodeficiency syndrome and Salmonella typhimurium bacteremia were identified over a 28-month period. In three patients bacteremia developed concurrently with an opportunistic infection associated with the acquired immunodeficiency syndrome. The remaining five patients had their initial episodes of bacteremia 3 to 11 months before the diagnosis of the acquired immunodeficiency syndrome. These five patients had signs suggestive of the syndrome, plus evidence of disordered cellular immune function (lymphopenia, anergy, decreased T-helper cells, decreased proliferative responses, and a deficiency in mononuclear-cell alpha interferon production). Salmonella typhimurium bacteremia in the appropriate clinical setting may be an opportunistic pathogen associated with the acquired immunodeficiency syndrome.
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000667:Ampicillin / Q000627:therapeutic use; D002701:Chloramphenicol / Q000627:therapeutic use; D003967:Diarrhea / Q000209:etiology; D004338:Drug Combinations / Q000627:therapeutic use; D005260:Female; D006205:Haiti / Q000208:ethnology; D006801:Humans; D008297:Male; D009519:New York City; D012008:Recurrence; D012480:Salmonella Infections / Q000209:etiology* / Q000276:immunology; D012486:Salmonella typhimurium; D018805:Sepsis / Q000209:etiology* / Q000276:immunology; D013420:Sulfamethoxazole / Q000627:therapeutic use; D014295:Trimethoprim / Q000627:therapeutic use; D015662:Trimethoprim, Sulfamethoxazole Drug Combination
D004338:Drug Combinations; D002701:Chloramphenicol; D000667:Ampicillin; D015662:Trimethoprim, Sulfamethoxazole Drug Combination; D014295:Trimethoprim; D013420:Sulfamethoxazole